Intravenous immunoglobulin treatment of spleen cells from patients with immune thrombocytopenia significantly increases the percentage of myeloid-derived suppressor cells

Br J Haematol. 2018 Apr;181(2):262-264. doi: 10.1111/bjh.14542. Epub 2017 Feb 6.

Rukhsana Aslam¹, W Richard Burack², George B Segel², Mark McVey^{1

3

4

5}, Stephen A Spence², John W Semple^{1

3

6

7

8

9}

¹ Keenan Research Centre for Biomedical Science of St. Michaels Hospital, Rochester, NY, USA.
² Departments of Medicine and Pathology, University of Rochester School of Medicine, Rochester, NY, USA.
³ Canadian Blood Services, Toronto, ON, Canada.
⁴ Departments of Physiology and Anesthesia, University of Toronto, Toronto, ON, Canada.
⁵ Department of Anesthesia and Pain Medicine, Hospital for Sick Children, Toronto, ON, Canada.
⁶ Department of Pharmacology, University of Toronto, Toronto, ON, Canada.
⁷ Department of Medicine, University of Toronto, Toronto, ON, Canada.
⁸ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
⁹ Division of Haematology and Transfusion Medicine, Lund University, Lund, Sweden.

No abstract available

Keywords: immune thrombocytopenia; intravenous immunoglobulin; myeloid derived suppressor cells.

Publication types